Columbus Circle Investors purchased a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 98,888 shares of the company’s stock, valued at approximately $6,023,000. Columbus Circle Investors owned 0.18% of Crispr Therapeutics as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the stock. Nikko Asset Management Americas Inc. raised its stake in shares of Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after acquiring an additional 906,006 shares during the last quarter. Orbimed Advisors LLC bought a new position in Crispr Therapeutics in the third quarter valued at approximately $21,167,000. Price T Rowe Associates Inc. MD grew its stake in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth approximately $4,366,000. Finally, River & Mercantile Asset Management LLP acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth approximately $4,032,000. Institutional investors and hedge funds own 49.84% of the company’s stock.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,618 shares of company stock worth $3,230,760. 21.40% of the stock is owned by insiders.
NASDAQ CRSP opened at $51.95 on Friday. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -112.93 and a beta of 3.20. The business has a 50 day moving average price of $61.06 and a 200-day moving average price of $52.69. Crispr Therapeutics AG has a 52 week low of $29.34 and a 52 week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Several analysts have issued reports on CRSP shares. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Piper Jaffray Companies restated a “buy” rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research note on Monday, December 16th. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Finally, TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $75.95.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.